NASDAQ:VBIV - VBI Vaccines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.89 -0.03 (-1.56 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$1.92
Today's Range$1.84 - $1.99
52-Week Range$1.14 - $4.34
Volume250,300 shs
Average Volume577,162 shs
Market Capitalization$179.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBIV
CUSIPN/A
Phone617-830-3031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$860,000.00
Book Value$1.88 per share

Profitability

Net Income$-38,990,000.00
Net Margins-6,345.29%

Miscellaneous

Employees103
Market Cap$179.63 million
OptionableOptionable

VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc (NASDAQ:VBIV) issued its earnings results on Friday, November, 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.02. The biopharmaceutical company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.24 million. VBI Vaccines had a negative return on equity of 56.88% and a negative net margin of 6,345.29%. View VBI Vaccines' Earnings History.

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release their next quarterly earnings announcement on Friday, February 8th 2019. View Earnings Estimates for VBI Vaccines.

What price target have analysts set for VBIV?

3 analysts have issued 12-month price objectives for VBI Vaccines' stock. Their predictions range from $9.00 to $12.00. On average, they expect VBI Vaccines' share price to reach $10.50 in the next year. This suggests a possible upside of 455.6% from the stock's current price. View Analyst Price Targets for VBI Vaccines.

What is the consensus analysts' recommendation for VBI Vaccines?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines.

Has VBI Vaccines been receiving favorable news coverage?

News headlines about VBIV stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. VBI Vaccines earned a news sentiment score of 2.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of VBI Vaccines' key competitors?

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the folowing people:
  • Mr. Jeff R. Baxter, CEO, Pres & Director (Age 58)
  • Dr. David Evander Anderson, Chief Scientific Officer (Age 49)
  • Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 64)
  • Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 42)
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 54)

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $1.89.

How big of a company is VBI Vaccines?

VBI Vaccines has a market capitalization of $179.63 million and generates $860,000.00 in revenue each year. VBI Vaccines employs 103 workers across the globe.

What is VBI Vaccines' official website?

The official website for VBI Vaccines is http://www.vbivaccines.com.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]


MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  363
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Featured Article: S&P 500 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel